Empyrean

Empyrean Neuroscience is a private biotechnology company developing neuroactive therapeutics for neuropsychiatric and neurologic disorders. The company is built around a proprietary genetic engineering platform designed to modify fungi and plants to produce therapeutic small molecules, including fungal alkaloids, cannabinoids, and other neuroactive compounds. Its disclosed pipeline has focused on central nervous system indications such as major depressive disorder, post-traumatic stress disorder, substance abuse and dependence, chronic pain, and broader neurologic disorders. Publicly available information indicates the company launched with a $22 million Series A financing and was pursuing IND-enabling work on a genetically engineered encapsulated mushroom-derived drug candidate. Overall, Empyrean appears to be a platform-oriented preclinical CNS biotech rather than a commercial-stage pharmaceutical company.